Treatment for Blood Clotting Disorder

Monday, 23 Dec 2013 05:25 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
The U.S. Food and Drug Administration has approved Novo Nordisk's drug Tretten to prevent bleeding in patients with a rare blood clotting disorder.

Patients with congenital Factor XIIIA-subunit deficiency do not make enough of the Factor XIII protein that is important for normal blood clotting, the FDA said. Factor XIII is composed of subunits A and B and Factor XIII deficiency is usually caused by a deficiency of the A subunit.
 
Tretten was studied in 77 patients with the disorder and was effective in preventing bleeding in 90 percent of the patients when given monthly, the FDA said. Side effects included headache, pain in the extremities and at the injection site.

Congenital Factor XIII affects an estimated one in 3 million people globally and is associated with life-threatening bleeding, impaired wound healing and miscarriage.

The drug is expected to generate sales of $84 million by 2018, according to the average estimate of three analysts polled by Thomson Reuters.

Novo Nordisk acquired the rights to Tretten from ZymoGenetics Inc in 2004. Novo agreed to pay a royalty on sales, although details of the royalty payment were not disclosed.

ZymoGenetics was acquired by Bristol Myers Squibb Co in 2010.

The product was approved last year in Europe and Canada. It is sold in Europe under the brand name NovoThirteen and contains the active substance catridecacog, which is structurally the same as the human Factor XIII A subunit. It is produced by genetically engineered yeast cells.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved